Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.

The vast majority of acute myeloid leukemia (AML) patients harboring an FLT3-ITD mutation experience relapse within a short period of time after discontinuation of chemotherapy.[1][1] Treatment options include experimental trials using FLT3-tyrosine kinase inhibitors (TKI) or allogeneic stem cell